Gedeon Richter Plc (www. gedeonrichter.com) JSC Gedeon Richter, headquartered in Hungary, is an innovative specialty pharmaceutical company. The Hungarian multinational company's activities are vertically integrated and include pharmaceutical manufacturing, research and development, sales and marketing. Richter's goal is to help society fight disease through innovative products and thereby help improve the quality of human life. Innovation and research into original drug molecules have been key elements of the company's strategy since its founding in 1901. With more than 1,200 employees in research and development. Richter is today the most significant pharmaceutical research base in the Central and Eastern European region. The Richter Group spent €154 million on research and development in 2020, representing 9.5 percent of its consolidated sales revenue. Drug research and development includes four strategic areas: recombinant biotechnology activities, new chemicals research and development, women's health projects and generic products. Pharmaceutical production in Richter, with a 120-year history, is at the forefront of the global industry in every respect. The company produces more than 200 types of pharmaceuticals, including original, generics, biosimilars and licensed drugs. The Gedeon Richter company traditionally uses its own active ingredients in its medicines and various preparations such as injections, creams, ointments. Gedeon Richter Plc (www.gedeonrichter.com), operating as JSC Gedeon Richter and headquartered in Hungary, is an innovative, research driven pharmaceutical company. The Hungarian multinational company operates a vertically integrated business model that includes pharmaceutical manufacturing, research and development, sales, and marketing. Richter’s mission is to help society fight diseases through innovative products and, in doing so, contribute to improving the quality of human life. Innovation and research into original drug molecules have been core elements of the company’s strategy since its foundation in 1901. Today, with more than 1,200 employees working in research and development, Richter represents the most significant pharmaceutical R&D base in Central and Eastern Europe. In 2020, the Richter Group invested EUR 154 million in research and development, accounting for 9.5% of its consolidated sales revenue. Drug research and development focuses on four strategic areas: recombinant biotechnology, research and development of new chemical entities, women’s healthcare projects, and generic products. Pharmaceutical manufacturing at Richter, with a 120 year history, is at the forefront of the global industry in every respect. The company produces more than 200 pharmaceutical products, including original medicines, generics, biosimilars, and licensed products. Richter traditionally uses its own active pharmaceutical ingredients in its medicines and manufactures a wide range of dosage forms, such as injections, creams, and ointments.